Nintedanib (n = 39) | Pirfenidone (n = 51) | p-value | |
---|---|---|---|
Age, years | 70 (7) | 72 (7) | 0.22 |
Male sex – no. (%) | 35 (90) | 47 (92) | 0.72 |
FVC % predicted | 86 (16) | 76 (16) | 0.01 |
FVC (L) | 3.4 (0.9) | 2.9 (0.6) | 0.01 |
DLCO % predicted | 48 (14) | 49 (14) | 0.69 |
K-BILD total score | 56.5 (9) | 56.7 (10) | 0.89 |
EQ 5D-Index value | 0.78 (0.15) | 0.77 (0.19) | 0.78 |
EQ5D-VAS scale | 65 (24) | 63 (23) | 0.66 |
VAS – cough* | 4.8 (2.6) | 4.6 (2.5) | 0.66 |
VAS – dyspnea* | 5.1 (2.3) | 5.6 (2.4) | 0.43 |
VAS – general complaints** | 5.6 (2.4) | 5.5 (2.4) | 0.75 |
HADS – depression score | 3.0 (3.1) | 3.9 (3.5) | 0.21 |
HADS – anxiety score | 4.7 (2.3) | 4.6 (2.3) | 0.94 |